Nat Commun July 2023 PMID 37500611

A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity.

Shuwei Liang, Eric Tran, Xin Du, Jiajun Dong, Harrison Sudholz, Hao Chen, Zihan Qu, Nicholas D Huntington, Jeffrey J Babon, Nadia J Kershaw, Zhong-Yin Zhang, Jonathan B Baell, Florian Wiede, Tony Tiganis

Download social card

Mentions

Peak: 3 in Jun 2023

across 2 sources since Jun 2023

Extended reach

140,276

potential audience

Total likes

Video views

140

Mentions per month

Jun 2023 – Oct 2023

Where it's discussed

X / Twitter4 posts
YouTube1 videos

AI synopsis

What people are saying

The consensus reflects cautious optimism about the study, as seen in comments that highlight the inhibitor's ability to boost immune responses and make resistant tumors more responsive to therapy. Words like 'enhances' and 'potential' demonstrate positive yet measured interest, with some mentioning its role in improving immunotherapy outcomes and researchers' excitement about the possibilities.

AgreementModerate agreement

Most discussions acknowledge the potential of the small molecule inhibitor in enhancing T cell anti-tumor activity, indicating general support for the findings.

InterestModerate interest

The discussions show moderate curiosity, with emphasis on the therapeutic implications and mention of the specific enzymes involved.

EngagementModerate engagement

Participants reference the research's impact on immunotherapy and highlight its significance, reflecting active engagement.

ImpactModerate impact

The discussions suggest that this research could influence future cancer treatments, emphasizing its potential importance.

Abstract in brief

The study investigates a small molecule inhibitor called Compound182 that targets PTP1B and PTPN2, enzymes involved in immune regulation, showing potential to boost T cell activity against tumors.
Compound182 enhances T cell recruitment and activation, reduces tumor growth in mice, and can make resistant tumors responsive to PD1 immunotherapy, all without significant immune-related side effects.
The findings suggest that inhibiting PTP1B and PTPN2 with small molecules could be a promising strategy for improving cancer immunotherapy outcomes.

Read the full abstract

All mentions

Enhancing T Cell Anti-Tumor Immunity with Small Molecule Inhibitors of PTP1B and PTPN2

A small molecule inhibitor called Compound182 targets enzymes involved in immune regulation, boosting T cell activity against tumors, reducing tumor growth, and enhancing responses to immunotherapy without significant…

STEM RTCL TV · Oct 19, 2023 140 views

L2P Research Labs

@l2presearch · X

A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity https://t.co/Cy5CB8gaxz

Jul 27, 2023 · 149 followers View post →

Victoria Hendry

@HendryVictoria · X

RT @biorxiv_cancer: A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity https://t.co/thZp2mW3RF #biorxiv_can…

Jun 16, 2023 · 1 share · 1,318 followers View post →

bioRxiv Cancer Bio

@biorxiv_cancer · X

A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity https://t.co/thZp2mW3RF #biorxiv_cancer

Jun 16, 2023 · 1 like · 1 share · 1,720 followers View post →

bioRxiv

@biorxivpreprint · X

A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity https://t.co/oVS2C1RQ0e #bioRxiv

Jun 16, 2023 · 1 like · 136,946 followers View post →